跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 7,768 条关于
“Secondary Hyperparathyroidism”
全部
7,768
临床试验
3,568
药物
26
机构
10
资讯
4,164
去年
Amgen Advances Phase 3 Study of Etelcalcetide for Pediatric Secondary Hyperparathyroidism
2年前
Unicycive Submits NDA to FDA for Oxylanthanum Carbonate to Treat Hyperphosphatemia in CKD Patients on Dialysis
去年
FDA Accepts Unicycive's Oxylanthanum Carbonate (OLC) Application for Hyperphosphatemia Treatment
去年
FDA Accepts Unicycive's NDA for Oxylanthanum Carbonate to Treat Hyperphosphatemia in CKD Patients on Dialysis
2个月前
Shaanxi Micot Advances First-in-Class Dual-Target Anticoagulant MT1002 into Phase II Hemodialysis Trial
上个月
Bone Resorption and Constipation Predict Higher Tenapanor Dose Requirements in Dialysis Patients with Hyperphosphatemia
去年
Unicycive's OLC Receives FDA Acceptance for Hyperphosphatemia NDA
去年
Alebund's AP301 Meets Primary Endpoint in Phase 3 Trial for Hyperphosphatemia in Dialysis Patients
去年
Debate Over CAR-T Therapy's Secondary Malignancy Risks Continues
去年
Alzheimer's Prevention Trials Update: Lecanemab, Donanemab, and Remternetug
第 1 页，共 417 页
上一页
下一页
